AbbVie Inc.

Rinvoq-specific data does not show the same magnitude of cardiovascular and malignancy risk as tofacitinib (ORAL Surveillance). The FDA black box warning is class-wide, not Rinvoq-specific. As real-world evidence accumulates, physicians may grow more comfortable. Rinvoq already at $8.3B and growing — the data speaks.

The FDA black box warning is permanent and limits formulary positioning. In rheumatology, Rinvoq is relegated to 2L+ after biologic failure. In dermatology and GI, where it could be 1L, the warning gives payers ammunition to require biologic step-therapy first. The $12B peak assumes progression to first-line in multiple indications — but the safety overhang may permanently cap it at $9-10B. Additionally, if any new JAK safety signal emerges (even from a competitor), it hits the entire class.

Ubrelvy ($1.15B) + Qulipta ($1.16B) = $2.3B combined FY25 and still growing double-digits. Migraine affects 39M Americans, chronic migraine is severely underdiagnosed. Qulipta is the only oral CGRP for prevention — differentiating from injectable competitors (Aimovig, Ajovy, Emgality). As migraine awareness grows, both drugs benefit. Combined peak could reach $5-6B. The franchise gets zero narrative airtime because Skyrizi ($17.6B) and Rinvoq ($8.3B) dominate every analyst note.

Migraine is competitive — multiple CGRPs, triptans are generic. Growth may plateau as easy patients are captured. The franchise is meaningful but not thesis-changing for a $60B revenue company.